Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of MV-ZIKA-RSP Vaccine in Healthy Adults
NCT04033068Phase 1Completed
- Sponsor
- Themis Bioscience
- Start
- Aug 2019
- Primary completion
- Jan 2020
- Modality
- Viral Vector Vaccines, Live Vector Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of MV-ZIKA-RSP in Zika virus infection (4 arms), sponsored by Themis Bioscience. Primary endpoint: Percentage of Participants Who Experienced an Adverse Event (AE). Started Aug 2019; status: completed.
02
Drugs
MV-ZIKA-RSP
03
Conditions
Zika virus infection
Beyond the preview
Go deeper on NCT04033068.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04033068.